Imperial College London
Alternate

ProfessorAndreaFrilling

Faculty of Medicine, Department of Surgery & Cancer

Chair in Endocrine Surgery
 
 
 
//

Contact

 

+44 (0)20 3313 3210a.frilling

 
 
//

Location

 

BN2/13 B BlockHammersmith HospitalHammersmith Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Modlin:2021:10.1016/j.annonc.2021.08.1746,
author = {Modlin, IM and Kidd, M and Falconi, M and Filosso, PL and Frilling, A and Malczewska, A and Toumpanakis, C and Valk, G and Pacak, K and Bodei, L and Öberg, KE},
doi = {10.1016/j.annonc.2021.08.1746},
journal = {Annals of Oncology},
pages = {1425--1433},
title = {A multigenomic liquid biopsy biomarker for neuroendocrine tumor disease outperforms CgA and has surgical and clinical utility.},
url = {http://dx.doi.org/10.1016/j.annonc.2021.08.1746},
volume = {32},
year = {2021}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - BACKGROUND: Biomarkers are key tools in cancer management. In neuroendocrine tumors (NETs), Chromogranin A (CgA) was considered acceptable as a biomarker. We compared the clinical efficacy of a multigenomic blood biomarker (NETest) to CgA over a 5-year period. PATIENTS AND METHODS: An observational, prospective, cross-sectional, multicenter, multinational, comparative cohort assessment. Cohort 1: NETest evaluation in NETs (n = 1684) and cancers, benign diseases, controls (n = 731). Cohort 2: (n = 1270): matched analysis of NETest/CgA in a sub-cohort of NETs (n = 922) versus other diseases and controls (n = 348). Disease status was assessed by response evaluation criteria in solid tumors (RECIST). NETest measurement: qPCR [upper limit of normal (ULN: 20)], CgA (EuroDiagnostica, ULN: 108 ng/ml). STATISTICS: Mann-Whitney U-test, AUROC, chi-square and McNemar' test. RESULTS: Cohort 1: NETest diagnostic accuracy was 91% (P < 0.0001) and identified pheochromocytomas (98%), small intestine (94%), pancreas (91%), lung (88%), gastric (80%) and appendix (79%). NETest reflected grading: G1: 40 ± 1, G2 (50 ± 1) and G3 (52 ± 1). Locoregional disease levels were lower (38 ± 1) than metastatic (52 ± 1, P < 0.0001). NETest accurately stratified RECIST-assessed disease extent: no disease (21 ± 1), stable (43 ± 2), progressive (62 ± 2) (P < 0.0001). NETest concordance with imaging (CT/MRI/68Ga-SSA-PET) 91%. Presurgery, all NETs (n = 153) were positive (100%). After palliative R1/R2 surgery (n = 51) all (100%) remained elevated. After curative R0-surgery (n = 102), NETest levels were normal in 81 (70%) with no recurrence at 2 years. In the 31 (30%) with elevated levels, 25 (81%) recurred within 2 years. Cohort #2: NETest diagnostic accuracy was 87% and CgA 54% (P < 0.0001). NETest was more accurate than CgA for grading (chi-square = 7.7, OR = 18.5) and metastatic identification
AU  - Modlin,IM
AU  - Kidd,M
AU  - Falconi,M
AU  - Filosso,PL
AU  - Frilling,A
AU  - Malczewska,A
AU  - Toumpanakis,C
AU  - Valk,G
AU  - Pacak,K
AU  - Bodei,L
AU  - Öberg,KE
DO  - 10.1016/j.annonc.2021.08.1746
EP  - 1433
PY  - 2021///
SN  - 0923-7534
SP  - 1425
TI  - A multigenomic liquid biopsy biomarker for neuroendocrine tumor disease outperforms CgA and has surgical and clinical utility.
T2  - Annals of Oncology
UR  - http://dx.doi.org/10.1016/j.annonc.2021.08.1746
UR  - https://www.ncbi.nlm.nih.gov/pubmed/34390828
UR  - https://www.sciencedirect.com/science/article/pii/S0923753421039752?via%3Dihub
UR  - http://hdl.handle.net/10044/1/91670
VL  - 32
ER  -
Download